Essex Bio-Technology's (HKG:1061) profit attributable to owners rose to HK$318.1 million for 2025, up from HK$307.2 million a year earlier, according to a Monday Hong Kong bourse filing.
Shares of the firm were up more than 1% in Tuesday morning trade.
Earnings per share came in at HK$0.5610, compared with HK$0.5318 a year earlier.
Revenue rose to HK$1.81 billion from HK$1.67 billion.
The board recommended a final dividend of HK$0.07 per share for 2025, payable on June 12 to shareholders whose names appear on the register of members as on June 3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments